BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30700352)

  • 1. Evaluation of an Image-based Automated Detection System in Detecting Ki67 Proliferation Index and Correlation with the Traditional Eye-Ball Method in Gastroenteropancreatic Neuroendocrine Tumors.
    Dere Y; Ozkaraca O; Cetin G; Dere O
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):137-140. PubMed ID: 30700352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
    Saetiew K; Angkathunyakul N; Hunnangkul S; Pongpaibul A
    Ann Diagn Pathol; 2024 Aug; 71():152295. PubMed ID: 38547761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Cytotechnologist Manual Counting Service for the Ki67 Index in Neuroendocrine Tumors of the Pancreas and Gastrointestinal Tract.
    Cottenden J; Filter ER; Cottreau J; Moore D; Bullock M; Huang WY; Arnason T
    Arch Pathol Lab Med; 2018 Mar; 142(3):402-407. PubMed ID: 29293020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G; La Rosa S
    Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Monitor-Image and Printout-Image Methods in Ki-67 Scoring of Gastroenteropancreatic Neuroendocrine Tumors.
    Dogukan FM; Yilmaz Ozguven B; Dogukan R; Kabukcuoglu F
    Endocr Pathol; 2019 Mar; 30(1):17-23. PubMed ID: 30367334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
    Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
    Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on grading and classification of neuroendocrine tumors.
    Kim JY; Hong SM; Ro JY
    Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
    Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
    Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
    Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis.
    Owens R; Gilmore E; Bingham V; Cardwell C; McBride H; McQuaid S; Humphries M; Kelly P
    Histopathology; 2020 Oct; 77(4):646-658. PubMed ID: 32617996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R
    Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.